Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Fuchs' endothelial dystrophy in which the cause of the disease is a mutation in the TCF4 gene.
Features include: Cloudy or opaque cornea (corneal opacity), Corneal stromal edema, Visual impairment, and Corneal guttata.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Cloudy or opaque cornea (corneal opacity), Corneal stromal edema, Visual impairment |
Pitt-Hopkins syndrome (PTHS) is characterized by distinctive facial features, significant developmental delays with moderate-to-severe intellectual disability, neurobehavioral/psychiatric manifestations (e.g., stereotypic hand movements, autism spectrum disorder), and autonomic dysfunction (e.g., episodic hyperventilation and/or breath-holding while awake). Speech is significantly affected. Although most individuals are nonverbal, receptive language is often stronger than expressive language. Other common findings are sleep disturbances, seizures, constipation, and severe myopia .
Table 2.
Pitt-Hopkins Syndrome: Frequency of Select Features
Feature | % of Persons w/Feature
Facial gestalt | 90%-95%
Developmental delay/ intellectual disability | 100%
Delayed motor milestones | 100%
Source: GeneReviews — "Pitt-Hopkins Syndrome"
TCF4 function has not been fully characterized.
Corneal dystrophy, Fuchs endothelial, 3 is associated with mutations in the TCF4 gene on chromosome 18.
Clinical and molecular diagnostic criteria for Pitt-Hopkins syndrome (PTHS) have been established [.]
PTHS should be suspected in a proband with the following clinical and imaging findings and family history.
Clinical findings
• Developmental delay/ intellectual disability
Delayed motor milestones, often associated with hypotonia
Severely limited-to-absent speech, with regression in verbal abilities in some individuals
Intellectual disability, typically moderate to severe
• Neurobehavioral/psychiatric manifestations
Source: GeneReviews — "Pitt-Hopkins Syndrome"
Disorders with features that overlap those of Pitt-Hopkins syndrome (PTHS) are listed in . Of these disorders, Rett syndrome and Angelman syndrome are the most common. Most of the disorders are distinguished from PTHS by the absence of typical PTHS facial features. Table 3. Disorders to Consider in the Differential Diagnosis of Pitt-Hopkins Syndrome
Gene(s)/ Genetic Alteration | Disorder | MOI | Common Features of Disorder |
|---|---|---|---|
ARX | ARX-related ID syndrome (OMIM 309510) | XL | DD, severe speech disorder, seizures; Recurrent hyperventilation episodes reported in 1 persons w/an ARX pathogenic variant. |
Genetic testing for TCF4 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for corneal dystrophy, Fuchs endothelial, 3 has been reported in the published literature.
No approved treatments are currently available for corneal dystrophy, Fuchs endothelial, 3. The disease remains an area of unmet medical need.
Gene therapy approaches for corneal dystrophy, Fuchs endothelial, 3 have been reported in the published literature.
Clinical practice guidelines for management of individuals with Pitt-Hopkins syndrome (PTHS) have been published .
To establish the extent of disease and needs in an individual diagnosed with PTHS, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Pitt-Hopkins Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| By child neurologist | • To establish a neurologic baseline evaluate for other neurologic issues such as sleep dysfunction or seizures
To incl brain MRI if not previously performed
Consider EEG if seizures are a concern.
| Developmental assessment | • To assess cognitive baseline determine the types of services educational strategies needed
For infants young children: evaluate for early intervention.
For school-age children: determine need for IEP or 504 plan.
| • By speech-language pathologist
By therapist trained in accessory augmentative communication
| To assess need for nonverbal communication devices strategies
| By child behavior specialist | Consider consultation w/child psychiatrist if behavioral issues are significant.
| By pediatric pulmonologist | • Assess for respiratory dysregulation, signs of chronic hypoxemia, and aspiration
Source: GeneReviews — "Pitt-Hopkins Syndrome"
View trials for corneal dystrophy, Fuchs endothelial, 3
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. Pitt-Hopkins Syndrome: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Development | Monitor developmental progress educational needs. | At each visit Feeding |
Ophthalmologic | Monitor for changes in refractive error (usually high myopia) strabismus. | Per treating ophthalmologist Low vision services |
Musculoskeletal | Physical medicine specialist OT/PT to assess mobility, need for orthotics, durable equipment, self-help skills | At each visit Assess for scoliosis. |
Family/Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit |
Transition to adult care | Develop plan for transition from pediatric to adult care.2 | Starting by age ~10 yrs ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; OT = occupational therapist; PT = physical therapist 1. |
Source: GeneReviews — "Pitt-Hopkins Syndrome"
No clinical trials have been registered for corneal dystrophy, Fuchs endothelial, 3.
181 publications have been identified in PubMed for corneal dystrophy, Fuchs endothelial, 3. Research spans Clinical Trial Publication (31%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 56 | 31% |
Laboratory research | 47 | 26% |
Disease patterns and progression | 32 | 18% |
Patient case studies | 16 | 9% |
Research summaries | 15 | 8% |
Testing and diagnosis research | 7 | 4% |
New treatment approaches | 7 | 4% |
Other research | 1 | 1% |
Wong TH (2026). [PMID: 42067464](https://pubmed.ncbi.nlm.nih.gov/42067464/). *J Formos Med Assoc*. [Diagnostic / Biomarker]
Gustavson BP (2026). [PMID: 41962907](https://pubmed.ncbi.nlm.nih.gov/41962907/). *Can J Ophthalmol*. [Diagnostic / Biomarker]
Flockerzi E (2026). [PMID: 41248687](https://pubmed.ncbi.nlm.nih.gov/41248687/). *Klinische Monatsblatter fur Augenheilkunde*. [Review / Meta-Analysis]
Nair S (2026). [PMID: 41485730](https://pubmed.ncbi.nlm.nih.gov/41485730/). *Survey of ophthalmology*. [Review / Meta-Analysis]
Reinprayoon U (2026). [PMID: 42125430](https://pubmed.ncbi.nlm.nih.gov/42125430/). *Clin Ophthalmol*. [Clinical Trial Publication]
Vähämäki IT (2026). [PMID: 42010886](https://pubmed.ncbi.nlm.nih.gov/42010886/). *Acta Ophthalmol*. [Epidemiology / Natural History]
Maeno S (2026). [PMID: 41944554](https://pubmed.ncbi.nlm.nih.gov/41944554/). *J Pathol*. [Basic Science / Preclinical]
Teo JXJ (2026). [PMID: 41562921](https://pubmed.ncbi.nlm.nih.gov/41562921/). *Med Sci (Basel)*. [Epidemiology / Natural History]
Meyer JJ (2026). [PMID: 42241014](https://pubmed.ncbi.nlm.nih.gov/42241014/). *Cornea*. [Epidemiology / Natural History]
Barosco G (2026). [PMID: 41379592](https://pubmed.ncbi.nlm.nih.gov/41379592/). *Eur J Ophthalmol*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:01 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
XL |
Severe DD, impaired speech language development, constipation, reflux; Adult phenotype may incl some PTHS facial features hyperventilation.1 |
Seizures are typically more severe w/early-onset intractable epilepsy.; Persistent feeding problems are more common.; Movement disorders: chorea, dystonia; Absence of characteristic PTHS facial gestalt in childhood |
CNTNAP2 | CNTNAP2-assoc intellectual disorder (Pitt-Hopkins like syndrome 1) (OMIM 610042) | AR | Severe global delays, lack of speech, stereotypies, seizures; Episodic hyperventilation episodes reported in 3 persons. |
Kleefstra syndrome | AD | Moderate-to-severe DD with absent speech, seizures, motor delays | Congenital abnormalities: cardiac, renal, urologic; Facial features distinct from PTHS FOXG1 |
FOXG1 syndrome | AD | Severe DD w/absent speech, seizures | Postnatal growth deficiency, progressive microcephaly, hyperkinetic/dyskinetic movement disorder; Absence of characteristic PTHS facial features |
MECP2 | Classic Rett syndrome (See MECP2 Disorders.) | XL | Autonomic dysfunction: episodic hyperventilation/apnea |
MEF2C | MEF2C-related NDD (OMIM 613443) | AD | Seizures, ID w/poor or absent speech, hypotonia, poor motor development, episodic hyperventilation; MRI findings: enlarged ventricles, thin corpus callosum |
NRXN1 | NRXN1-assoc intellectual disorder (Pitt-Hopkins-like syndrome 2) (OMIM 614325) | AR | Severe global delays, lack of speech, stereotypies; Episodic breathing abnormalities in 3 persons (2 w/hyperventilation episodes; 1 w/breath-holding episodes) |
RHOBTB2 | RHOBTB2-related DEE (OMIM 618004) | AD | Global DD, seizures |
Source: GeneReviews — "Pitt-Hopkins Syndrome"